MEDICATIONS FOR OUD / NALTREXONE

Naltrexone Explained: How It Works for Opioid Use Disorder

A plain-language guide to naltrexone — the only non-opioid FDA-approved medication for OUD — how it works, what the opioid-free requirement means, and when it may be the right fit.
EVIDENCE LEVEL: ESTABLISHED / CLINICAL GUIDANCE

Naltrexone is the third FDA-approved medication for opioid use disorder and is fundamentally different from buprenorphine and methadone: it does not activate opioid receptors at all. Instead, it blocks them completely. This makes it the only option that involves no opioid agonist activity whatsoever — but it also comes with important requirements and considerations.

Quick Answer Naltrexone is an opioid antagonist — it blocks opioid receptors, preventing any opioid from producing its effects. It requires 7–10 days of complete opioid abstinence before starting. It does not produce physical dependence. Available as a daily oral tablet (ReVia) or a monthly injection (Vivitrol). Evidence supports its effectiveness for motivated patients who have completed opioid detox. [1]

What Naltrexone Is

Naltrexone is an opioid antagonist — it binds to mu-opioid receptors with high affinity and blocks them, preventing any opioid from producing its usual effects. If a person on naltrexone uses an opioid, they will feel little or no euphoria or analgesic effect, because the receptors are blocked.

Unlike buprenorphine and methadone, naltrexone:

  • Has no opioid agonist activity — it does not activate receptors, it only blocks them
  • Does not produce physical dependence — stopping naltrexone does not cause withdrawal
  • Does not help manage withdrawal symptoms — it must be started after opioids have fully cleared

Note: Naltrexone is also FDA-approved for alcohol use disorder, where it reduces cravings and heavy drinking. [1]

Formulations

Oral Naltrexone (ReVia, generics)

  • Taken as a daily pill (typically 50 mg/day)
  • Requires daily commitment and consistent adherence
  • Research shows adherence can be a significant barrier — a missed dose removes protection quickly
  • Lower cost than extended-release; may be preferred in some insurance contexts

Extended-Release Injectable Naltrexone (Vivitrol)

  • A once-monthly subcutaneous injection administered by a clinician
  • Eliminates daily adherence requirements — a single injection provides 30 days of continuous opioid blockade
  • Higher upfront cost; many insurance plans cover it
  • Evidence supports significantly better outcomes compared to oral naltrexone due to improved adherence
  • Particularly used in criminal justice settings, post-incarceration (a high-risk period), and for people who prefer a non-agonist approach

The Opioid-Free Requirement

This is the most critical aspect of naltrexone initiation and the most common source of complications. Because naltrexone blocks opioid receptors, it will precipitate immediate, severe withdrawal if started while opioids are still present in the system.

  • For short-acting opioids (heroin, oxycodone): a minimum of 7–10 days fully opioid-free
  • For long-acting opioids (methadone): up to 14–21 days opioid-free may be required
  • For buprenorphine: typically 7–14 days after the last buprenorphine dose

This opioid-free requirement is the major barrier to naltrexone initiation — many people are unable to achieve the required period of abstinence before starting. This is not a failure — it reflects the nature of OUD and the neurobiological drivers of withdrawal and craving. If naltrexone hasn’t been tolerable due to this barrier, buprenorphine or methadone — which can be started with opioids still present — may be more appropriate alternatives.

Do not start naltrexone without clinical confirmation that you have been opioid-free for the required period. Precipitated withdrawal from naltrexone initiation is sudden and severe. A naloxone challenge test or urine drug screen may be used by your clinician to verify safety before induction.

How Naltrexone Supports Recovery

The mechanism is straightforward: if opioid use does not produce its usual reinforcing effect (because receptors are blocked), the behavioral drive to seek and use opioids diminishes over time. This pharmacological extinction of the opioid use behavior is the primary therapeutic mechanism.

Additionally, by removing euphoria as a possible outcome of opioid use, naltrexone can help break the cycle of impulsive use that characterizes relapse — particularly in people who use due to situational triggers rather than severe physical dependence.

What the Evidence Shows

The evidence for naltrexone is supportive but more nuanced than for buprenorphine or methadone:

  • Extended-release naltrexone (Vivitrol) has strong evidence for reducing relapse in people who have successfully completed detox. [1]
  • Adherence is significantly better with injectable vs. oral formulations.
  • Head-to-head studies comparing extended-release naltrexone with buprenorphine show comparable outcomes when both treatments are successfully initiated — but induction failure (inability to get opioid-free for long enough to start) is a significant issue for naltrexone. [2]
  • Naltrexone is particularly well-studied in post-incarceration populations, where it has shown meaningful reductions in relapse and overdose. [1]

Who May Benefit Most From Naltrexone

  • People who are highly motivated and have completed a supervised opioid detox
  • People who prefer a non-opioid treatment option — whether due to personal values, professional requirements, or other reasons
  • People with legal or professional contexts where agonist medications are restricted or not preferred (e.g., healthcare workers under monitoring agreements — though this is nuanced and should be discussed with a clinician)
  • People transitioning out of incarceration, where the risk of relapse and overdose is extremely high (tolerance drops during incarceration)
  • People with co-occurring alcohol use disorder (naltrexone treats both)

Important Cautions

  • Reduced tolerance during treatment: While on naltrexone, opioid tolerance decreases. If naltrexone is discontinued and opioids are used at a previous dose, a fatal overdose can occur. This is one of the most dangerous aspects of naltrexone discontinuation.
  • Pain management: If opioid analgesia is needed while on naltrexone (e.g., for surgery), managing this requires careful clinical coordination. Non-opioid analgesia should be used where possible. In emergencies, very high-dose opioids may be needed to overcome the block.
  • Liver considerations: Naltrexone is metabolized by the liver. At very high doses, it can cause liver damage — though standard therapeutic doses are generally safe. Liver function should be monitored.

Questions to Ask a Clinician

  • Am I a good candidate for naltrexone given my history and current situation?
  • How long exactly do I need to be opioid-free before starting?
  • Is oral or injectable naltrexone better for my situation?
  • How will you confirm it’s safe to start?
  • What happens if I need opioids for pain while on naltrexone?
  • What should I know about the risk if I stop naltrexone and then use opioids?

Key Takeaways

  • Naltrexone is an opioid antagonist — it blocks opioid receptors without activating them.
  • It is the only FDA-approved OUD medication without opioid agonist activity.
  • It requires 7–10+ days of complete opioid abstinence before initiation.
  • Precipitated withdrawal from premature initiation is severe — clinical supervision is essential.
  • Extended-release injectable (Vivitrol) has better adherence than daily oral tablet.
  • Discontinuing naltrexone and then returning to opioid use is a high-risk period for overdose due to lost tolerance.

Related Resources

Sources

  1. SAMHSA. Medications for Opioid Use Disorder: TIP 63. 2021. SAMHSA.gov
  2. Lee JD, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT). Lancet. 2018;391(10118):309-318. PubMed
  3. CDC. Evidence-Based Strategies for Preventing Opioid Overdose. CDC.gov

This page provides general educational information. Naltrexone initiation and management require clinical supervision.